- Home
- CNTB vs EYEN Comparison
CNTB vs EYEN Comparison
Compare CNTB & EYEN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CNTB
- EYEN
- Stock Information
- Founded
- CNTB 2012
- EYEN 2014
- Country
- CNTB United States
- EYEN United States
- Employees
- CNTB N/A
- EYEN N/A
- Industry
- CNTB Biotechnology: Pharmaceutical Preparations
- EYEN Biotechnology: Pharmaceutical Preparations
- Sector
- CNTB Health Care
- EYEN Health Care
- Exchange
- CNTB Nasdaq
- EYEN Nasdaq
- Market Cap
- CNTB 68.5M
- EYEN 38.2M
- IPO Year
- CNTB 2021
- EYEN 2018
- Fundamental
- Price
- CNTB $1.17
- EYEN $0.55
- Analyst Decision
- CNTB Strong Buy
- EYEN Strong Buy
- Analyst Count
- CNTB 1
- EYEN 2
- Target Price
- CNTB $8.00
- EYEN $12.00
- AVG Volume (30 Days)
- CNTB 24.6K
- EYEN 879.0K
- Earning Date
- CNTB 09-05-2024
- EYEN 11-11-2024
- Dividend Yield
- CNTB N/A
- EYEN N/A
- EPS Growth
- CNTB N/A
- EYEN N/A
- EPS
- CNTB N/A
- EYEN N/A
- Revenue
- CNTB $24,116,000.00
- EYEN $31,405.00
- Revenue This Year
- CNTB N/A
- EYEN $50,309.30
- Revenue Next Year
- CNTB $63.90
- EYEN $421.63
- P/E Ratio
- CNTB N/A
- EYEN N/A
- Revenue Growth
- CNTB N/A
- EYEN N/A
- 52 Week Low
- CNTB $0.68
- EYEN $0.37
- 52 Week High
- CNTB $2.84
- EYEN $2.57
- Technical
- Relative Strength Index (RSI)
- CNTB 44.02
- EYEN 52.60
- Support Level
- CNTB $1.18
- EYEN $0.52
- Resistance Level
- CNTB $1.26
- EYEN $0.59
- Average True Range (ATR)
- CNTB 0.07
- EYEN 0.05
- MACD
- CNTB -0.01
- EYEN 0.01
- Stochastic Oscillator
- CNTB 13.59
- EYEN 66.45
About CNTB Connect Biopharma Holdings Limited
Connect Biopharma Holdings Ltd is a clinical-stage company focused on the discovery and development of next-generation immune modulators for the treatment of serious autoimmune diseases and inflammation. It has leveraged its expertise in the biology of T cell modulation to build a portfolio of drug candidates consisting of small molecules and antibodies targeting critical pathways of inflammation. Its pipeline includes CBP-201, CBP-307 and CBP-174.
About EYEN Eyenovia Inc.
Eyenovia Inc is a clinical stage ophthalmic company developing a pipeline of therapeutics based on its propriety array print (MAP) platform technology. It aims to achieve clinical microdosing of next-generation formulations of novel and existing ophthalmic pharmaceutical agents using its high-precision targeted ocular delivery system, branded the Opejet, which has the potential to replace conventional eye dropper delivery and improve safety, tolerability, patient compliance and topical delivery success for ophthalmic eye treatments. Using its proprietary delivery technology, Eyenovia is developing the next generation of smart ophthalmic therapies which target new indications or new combinations.